On this page
What tesamorelin before-and-after results have people reported?
Public accounts include a leaner waist, weight loss during a calorie deficit, lower reported visceral-fat measurements, and a tighter midsection with unchanged weight. The three examples below measure different things.
| Public account | Reported change | Actual checkpoint |
|---|---|---|
| Three-month report | 185 → 169 lb Scale weight | Completed approximately three months1 |
| 12-week scan report | 201 → 136 cm² Reported DEXA visceral-fat estimates | Week-four scan to end of a 12-week course2 |
| 8-week update | 90.4 kg, essentially stable Tighter midsection described | Week-eight update5 |
How to read these accounts: these are selected public first-person reports, not verified customers or typical outcomes. Identities, products and measurements were not independently verified. Diet, training and other treatments prevent isolating tesamorelin’s contribution. Reported doses provide context, not a recommended protocol.
What changed after a completed three-month course?
A 29-year-old man reported losing 16 lb while maintaining strength. He described starting in February 2026 at 185 lb and reaching 169 lb after approximately three months. His body-fat estimates changed from about 18% to 14%; these were estimates, not scan-confirmed measurements.1
He reported 1 mg tesamorelin each morning while fasted, 300 mcg ipamorelin daily, and 3 g creatine daily. The same period included a roughly 500-calorie deficit, 180 g protein daily, lifting twice weekly and triathlon training.
His clearest changes were in the lower belly, waist and overall leanness. In a follow-up, he placed the first noticeable physical changes in month two; better sleep and water retention came earlier. Strength maintenance was his impression, with no recorded lifts supplied.1
The 16 lb figure describes the outcome of the entire regimen. It cannot establish how much weight tesamorelin itself caused him to lose.
How much visceral fat changed on the reported scans?
On April 16, 2026, a TexAgs poster reported completing a 12-week course. The reported DEXA visceral-fat estimate fell from 201 cm² to 136 cm². Crucially, the first scan was taken four weeks into treatment: the comparison spans eight weeks, not the full course and not a pretreatment baseline.2
An earlier post described tesamorelin at 2 mg per day, five days on and two off.4 Other posts disclosed ipamorelin, retatrutide started in January, substantial concurrent weight loss, and a wider peptide regimen.3 At completion, the author also reported worse insulin-resistance markers and planned repeat bloodwork.2
This is a specific numerical account, but the scans were not independently authenticated. It cannot be ranked against a clinical trial: the treatment combination, measurement method, starting point and comparison all differ.
Can the midsection look tighter without weight loss?
That is what the author of the eight-week update described. At 90.4 kg, the author said weight had stayed essentially unchanged since starting, while the midsection looked tighter and workout performance improved. No numerical waist reduction or follow-up scan was provided.5
The author later reported 2 mg tesamorelin daily. The original post described roughly 1,900 calories per day, training five days weekly, daily cardio and at least 10,000 steps. Flu and a stomach virus had interrupted weeks three and four.
Follow-ups disclosed retatrutide, ipamorelin and GLOW. The author also credited DSIP and a consistent eight-to-nine-hour sleep schedule for part of the performance improvement.5
This was an update during use, not a completed course or evidence of maintained results after stopping. The account supports a reported appearance change; it does not quantify fat lost or muscle gained.
How long does tesamorelin take to show results?
| Timepoint | What the evidence here actually shows |
|---|---|
| First month | No dependable visual-result deadline can be established from these accounts. |
| Around 7–8 weeks | Mixed interim reports: appearance changes for some, little observed change for another.567 |
| Around three months | The completed-course weight and scan reports above.12 |
| 26 weeks | The main visceral-fat endpoint in the pooled placebo-controlled trials.8 |
The variation matters. A 45-year-old woman described a smaller waist and better recovery around weeks seven to eight while also using retatrutide. Her reported sequence was 1 mg tesamorelin nightly, then 2 mg, then a 0.6 mg tesamorelin/200 mcg ipamorelin blend. She also reported hand numbness and IGF-1 rising from 189 to 373 ng/mL. Twelve weeks was her plan, not a completed outcome.6
By contrast, the author of a two-month no-change report described no noticeable progress after roughly two months despite regular gym sessions and increased protein. The author described 2,300 calories daily, had no follow-up scan yet, and gave inconsistent dose figures. The post cannot establish either adequate exposure or unchanged visceral fat.7 See the benefits page for the wider set of public accounts.
Why can waist size change before scale weight?
Waist size and body weight measure different outcomes. In the two pivotal studies, average waist changes at 26 weeks were approximately −3 cm and −2 cm with tesamorelin, versus −1 cm with placebo. Average weight changes in the treated groups were only −0.4 kg and +0.5 kg.9
The same studies reported lower trunk fat and higher lean mass. Those opposing changes help explain why a smaller waist need not produce a large scale change. Fluid retention is also a labeled effect. However, an individual weight plateau does not by itself prove fat loss, muscle gain or retained water.9
What can before-and-after photos actually prove?
Photos can document outward appearance. They cannot measure fat around the organs, establish a body-fat percentage or isolate which treatment caused a change. A fair visual comparison needs similar posture, lighting, clothing and camera distance; a flexed, differently lit “after” photo answers less than it appears to.
The clinical benchmark is more specific: a pooled trial analysis involving 806 adults with HIV and excess abdominal fat found a 15.4% relative treatment effect versus placebo on CT-measured visceral fat at 26 weeks. That is not 15.4% of body weight lost and not a 15.4-percentage-point fall in body fat.8
The same analysis did not demonstrate a significant reduction in abdominal subcutaneous fat, the layer under the skin. A visibly leaner stomach and reduced visceral fat are therefore related questions with different measurements.8
Do tesamorelin results last after you stop?
Clinical withdrawal data show visceral fat reaccumulating after treatment stopped. In a 52-week study, participants continuing tesamorelin maintained approximately an 18% reduction from their original visceral-fat baseline. Participants switched from tesamorelin to placebo after week 26 reaccumulated visceral fat.10
A photo or measurement at the end of a three-month course therefore cannot establish a permanent result. The study also cannot predict a particular person’s speed or amount of regain. The public examples above provide no verified long-term maintenance measurements after discontinuation.
Tesamorelin results FAQ
How many pounds should someone expect to lose?
There is no dependable pounds-lost figure. The approved medicine is described as weight neutral and is not indicated for weight-loss management. A community account combining several treatments with a calorie deficit cannot supply an expected tesamorelin-only result.9
Do these reports prove that adding ipamorelin improves results?
No. These accounts do not compare otherwise similar people using tesamorelin alone versus a blend. They document what the authors used; they cannot measure the extra contribution of ipamorelin. Read the tesamorelin and ipamorelin guide for the combination’s evidence and dosing questions.
Where are the daily doses, cycles and reconstitution details?
The dosage and protocol guide covers formulation-specific dosing, cycle claims, mixing and the calculator. The side-effects guide explains glucose, IGF-1 and fluid-retention monitoring.
Sources for the results and timelines
- 1Three-month tesamorelin/ipamorelin report.
- 212-week scan report: course completion, April 16, 2026.
- 312-week scan report: concurrent retatrutide, ipamorelin and weight-loss context.
- 412-week scan report: earlier reported tesamorelin schedule.
- 58-week update and author follow-ups.
- 645-year-old woman: interim appearance, recovery and IGF-1 report.
- 72-month no-change report.
- 8Falutz et al. Pooled phase III trials. CT-measured visceral fat at 26 weeks.
- 9EGRIFTA WR prescribing information. Weight, waist, body composition and fluid retention.
- 10Falutz et al. Fifty-two-week treatment and withdrawal study.